GlassScriptPhysician profile
Pedro Garciarena
NPI 1508038431
$13,681.29
in general payments reported to CMS, 2019-2025
71 companies · $3,650 in 2025
The $3,650 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,194 · 2020: $505 · 2021: $1,222 · 2022: $663 · 2023: $1,657 · 2024: $3,789 · 2025: $3,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,096.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,705.66 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Abbvie INC. | $1,364.13 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $836.13 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $710.79 | 2019-2025 | |
| Eisai INC. | $642.93 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $620.83 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $574.16 | 2019-2025 | Uplizna |
| Acorda Therapeutics, INC | $389.64 | 2019-2023 | Inbrija, Ampyra |
| Neurocrine Biosciences, INC. | $366.72 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $362.72 | 2019-2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $310.27 | 2022-2024 | Onpattro |
| Lilly USA, LLC | $292.65 | 2019-2025 | Amyvid, Kisunla |
| Allergan, INC. | $284.01 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.62 | 2019-2022 | |
| Biogen, INC. | $254.33 | 2019-2025 | Vumerity |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Garciarena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.